Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
May 09, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm,...
Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 09, 2024 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:45 ET
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 09, 2024 07:00 ET
|
Larimar Therapeutics
First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated...
Alector to Participate in Upcoming Healthcare Conferences
May 09, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
lowRISC Deploys Real Intent Ascent Lint, Meridian CDC, & Meridian RDC for OpenTitan Project
May 09, 2024 06:30 ET
|
Real Intent
lowRISC is deploying Real Intent Ascent Lint, Meridian CDC, & Meridian RDC for OpenTitan Project
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:05 ET
|
Alector, Inc.
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments:...
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024 16:05 ET
|
Design Therapeutics, Inc.
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 08, 2024 11:31 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...